YH 14618

Drug Profile

YH 14618

Alternative Names: P2K; Peniel 2K; Peniel-2000; YH14618

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Ensol Biosciences
  • Class Peptides; Small molecules
  • Mechanism of Action Transforming growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 01 Aug 2016 Yuhan Corporation completes a phase IIb trial for Intervertebral disc degeneration in South Korea (NCT02320019)
  • 01 Mar 2015 Phase-II clinical trials in Intervertebral disc degeneration in South Korea (Intra-articular) (NCT02320019)
  • 23 Dec 2014 Yuhan Corporation plans a phase IIb trial for Intervertebral disc degeneration in South Korea (NCT02320019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top